Format

Send to

Choose Destination
Am J Surg. 2009 Apr;197(4):466-72. doi: 10.1016/j.amjsurg.2007.12.057. Epub 2008 Jul 17.

Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma.

Author information

1
Division of Surgery and Oncology, School of Cancer Studies, Royal Liverpool University Hospital, Liverpool, UK. rsmith3@liverpool.ac.uk

Abstract

BACKGROUND:

The objective of this study was to investigate whether the preoperative platelet-lymphocyte (P/L) ratio represents a significant prognostic index in resected pancreatic ductal adenocarcinoma.

METHODS:

A total of 110 patients undergoing pancreatoduodenectomy for pancreatic ductal adenocarcinoma over a 10-year period were identified from a prospectively maintained database.

RESULTS:

The preoperative P/L ratio was found to be a more significant prognostic marker (P < .001) than either the lymphocyte count (P = .007) or platelet count (P = .068) on univariate Cox survival analysis. The median overall survival in patients with a P/L ratio of 150 or less (n = 48) was 19.7 months, 13.7 months in those with a P/L ratio of 151 to 300 (n = 43), and 5.8 months in patients with a value of greater than 300 (n = 19) (log-rank, P = .006). The preoperative P/L ratio retained significance on multivariate analysis (P < .001), along with tumor size (P = .010) and lymph node ratio (P = .013).

CONCLUSIONS:

The preoperative P/L ratio represents a significant independent prognostic index in patients of resected pancreatic adenocarcinoma.

PMID:
18639229
DOI:
10.1016/j.amjsurg.2007.12.057
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center